Pharmaceutical Technology
JULY 15, 2022
Most of the US insulin market is controlled by three pharma companies: Sanofi, Eli Lilly, and Novo Nordisk. For almost all their insulin, these companies manufacture the API and finished dose in-house and package the products themselves instead of using CMOs, GlobalData’s Drugs database shows.
Pharmaceutical Technology
MARCH 24, 2023
Many pharma companies hold extensive patent protections and have ongoing patent litigation cases. Advocacy groups, like Biosimilar Forum, have highlighted issues around formulary access for the new biosimilars and questioned if pharmacy benefit managers (PBMs) will offer all the Humira biosimilar options on their formularies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 8, 2021
The global pandemic has caused pharma companies to invest in digital marketing, as healthcare systems across the world adapt to strict lockdown rules. Healthcare companies have been in the vanguard of this change, with an enormous rise in the use of telehealth and all forms of digital communications. Will we go back to that?
XTalks
SEPTEMBER 11, 2023
The first ten drugs to undergo Medicare drug price negotiations were chosen based on criteria determined by Medicare, which include that they be sold in pharmacies, not have significant generic competition and have been on the market for at least nine years (13 years for more complex biologics).
pharmaphorum
AUGUST 20, 2020
Shares in Teva were down sharply this week after the US Department of Justice filed a complaint that the company paid illegal kickbacks to patient groups to boost sales of its multiple sclerosis drug Copaxone (glatiramer). The allegation is that Teva’s subsidiaries Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc.
XTalks
NOVEMBER 2, 2023
It is specifically approved as an interchangeable biosimilar, which means it may be substituted for the original product at the pharmacy level by a pharmacist without the need for a healthcare professional to prescribe the change. billion in sales, accounting for ten percent of Johnson & Johnson’s revenue.
pharmaphorum
JUNE 10, 2021
If pharmaceutical companies’ steady price increases are wholly due to limitless greed or thirst for revenue growth, this certainly is not proven by the actual, factual financial results for these same companies. These payers are best defined as entities that pay for or reimburse pharmacies for drugs dispensed to covered patients.
Expert insights. Personalized for you.
328 
Let's personalize your content